| |
| |
| Exchange: |
N/A |
| Security
Type: |
N/A |
| Shares
Out: |
57,860,000 |
| Market
Cap: |
227.39(M) |
| Last
Volume: |
0 |
Avg
Vol: |
0 |
| 52
Week Range: |
$1.47 - $11.89 |
|
| Level
I Sector: |
N/A |
| Level
II Sector: |
N/A |
| Level
III Sector: |
N/A |
|
Member Indexes:
|
Rankings:
|
|
| Insider 3 Months : 14.8 |
| Insider 6 Months : 14.8 |
| Insider 3/6 Months : 29.9 |
|
| Guru Rank Number : - |
| Guru Rank Value : - |
| Guru Occurances : - |
|
|
|
|
|
| |
|
Company Profile Aldeyra Therapeutics is a biotechnology company focused on discovering and developing therapies designed to treat immune-mediated diseases. Co.'s primary product candidate, reproxalap, is a treatment in late-stage development for dry eye disease and allergic conjunctivitis. Co. has additional product candidates in development for autoimmune diseases and other immune-mediated disease, as well as for proliferative vitreoretinopathy (PVR) and other retinal diseases. Co. has rights to ADX-2191, a vitreous-compatible methotrexate formulation for intraocular injection, for the prevention of PVR, a retinal disease, and primary vitreoretinal lymphoma, a rare cancer.
|
|
|
D/I:
|
|
|
D
is for direct shares.
I is
for indirect shares.
D/I
refers to the Direct or Indirect
shares traded vs. held. |
|
|
|
Forms:
|
|
|
A
Form 4 is a form filed
by an insider to indicate a change
in ownership.
A Form
3 is a form filed by
an insider to indicate an
initial ownership of a security. |
|
|
|
3m +/-:
|
|
|
|
This
represents the company's 3 month
price change. The initial price
is based on the closing price
of the stock on the day the transaction
took place. Purchases & sales
are viewed as long & short
positions respectively.
|
|
|
|
Actions:
|
|
|
| B |
Buy |
| S |
Sell |
| OE |
Option
Exercised |
| A |
Acquired |
| D |
Disposed |
| AB |
Automatic
Buy |
| AS |
Automatic
Sell |
| IO |
Initial
Ownership |
|
|
|
|
Download:
|
|
|
Download only Transactions
Forms. (Default)
Download
only Summary Infomation.
Download
both Transactions and Summary Data
|
|
|
|
|
| |
| |
Summary (Direct Transactions Only)  |
3 Months |
6 Months |
12 Months |
24 Months |
| Total Shares Bought |
682,265 |
682,265 |
682,265 |
2,150,494 |
| Total Buy Value |
$2,768,372 |
$2,768,372 |
$2,768,372 |
$11,311,413 |
| Total People Bought |
1 |
1 |
1 |
3 |
| Total Buy Transactions |
5 |
5 |
5 |
17 |
| Total Shares Sold |
250,945 |
250,945 |
3,007,444 |
3,007,444 |
| Total Sell Value |
$805,803 |
$805,803 |
$5,259,111 |
$5,259,111 |
| Total People Sold |
3 |
3 |
4 |
4 |
| Total Sell Transactions |
7 |
7 |
9 |
9 |
| End Date |
2024-01-28 |
2023-10-27 |
2023-04-28 |
2022-04-28 |
|
| Filer's Name |
Relation Title |
Off-Dir-10% |
Tran. Date |
Form |
Action |
Price |
Mkt Value |
D/I |
Shares |
Holdings |
Rank
|
|
|
| 3m +/- |
|
|
Form |
  Brady Todd C |
President and CEO |
• • – |
2020-03-02 |
4 |
A |
$0.00 |
$0 |
D/D |
250,000 |
902,216 |
|
- |
|
| Brady Todd C |
President and CEO |
• • – |
2019-12-16 |
4 |
B |
$5.10 |
$101,908 |
D/D |
20,000 |
652,216 |
2.81 |
- |
|
| Brady Todd C |
President and CEO |
• • – |
2019-09-30 |
4 |
AB |
$5.68 |
$49,483 |
D/D |
8,710 |
632,216 |
|
- |
|
| Brady Todd C |
President and CEO |
• • – |
2019-09-23 |
4 |
AB |
$5.81 |
$50,433 |
D/D |
8,680 |
623,506 |
|
- |
|
| Brady Todd C |
President and CEO |
• • – |
2019-09-18 |
4 |
B |
$5.91 |
$84,465 |
D/D |
14,288 |
614,826 |
2.81 |
- |
|
| Bronstein Ben |
Director |
– • – |
2019-09-17 |
4 |
B |
$5.85 |
$9,945 |
D/D |
1,700 |
18,644 |
2.39 |
- |
|
| Brady Todd C |
President and CEO |
• • – |
2019-09-16 |
4/A |
B |
$6.03 |
$18,090 |
D/D |
3,000 |
600,538 |
2.81 |
- |
|
| Brady Todd C |
President and CEO |
• • – |
2019-09-16 |
4 |
B |
$6.03 |
$18,090 |
D/D |
3,000 |
591,991 |
2.81 |
- |
|
| Brady Todd C |
President and CEO |
• • – |
2019-09-13 |
4/A |
B |
$5.90 |
$109,359 |
D/D |
18,547 |
597,538 |
2.81 |
- |
|
| Douglas Richard |
Director |
– • – |
2019-09-13 |
4 |
B |
$6.00 |
$30,000 |
D/D |
5,000 |
85,000 |
2.39 |
- |
|
| Brady Todd C |
President and CEO |
• • – |
2019-09-13 |
4 |
B |
$5.79 |
$57,900 |
D/D |
10,000 |
588,991 |
2.81 |
- |
|
| Joyce Martin Joseph |
Director |
– • – |
2019-09-12 |
4 |
B |
$5.86 |
$9,964 |
D/D |
1,700 |
19,644 |
2.39 |
- |
|
| Douglas Richard |
Director |
– • – |
2019-09-12 |
4 |
B |
$6.03 |
$60,276 |
D/D |
10,000 |
80,000 |
2.39 |
- |
|
| Douglas Richard |
Director |
– • – |
2019-09-11 |
4 |
B |
$5.75 |
$57,529 |
D/D |
10,000 |
70,000 |
2.39 |
- |
|
| Brady Todd C |
President and CEO |
• • – |
2019-09-10 |
4 |
B |
$5.39 |
$53,937 |
D/D |
10,000 |
578,991 |
2.81 |
- |
|
| Douglas Richard |
Director |
– • – |
2019-09-10 |
4 |
B |
$5.09 |
$50,857 |
D/D |
10,000 |
60,000 |
2.39 |
- |
|
| Brady Todd C |
President and CEO |
• • – |
2019-09-09 |
4 |
B |
$4.89 |
$48,887 |
D/D |
10,000 |
568,991 |
2.81 |
- |
|
| Douglas Richard |
Director |
– • – |
2019-09-09 |
4 |
B |
$4.91 |
$49,106 |
D/D |
10,000 |
50,000 |
2.39 |
- |
|
| Clark David J |
Chief Medical Officer |
• – – |
2019-09-06 |
4 |
B |
$5.06 |
$25,311 |
D/D |
5,000 |
17,878 |
2.74 |
- |
|
| Mcmullin David |
Chief Commerical Officer |
• – – |
2019-09-05 |
4 |
B |
$4.68 |
$20,260 |
D/D |
4,329 |
6,148 |
2.74 |
- |
|
| Reed Joshua |
Chief Financial Officer |
• – – |
2019-09-05 |
4 |
B |
$4.71 |
$15,072 |
D/D |
3,200 |
35,774 |
2.74 |
- |
|
| Treu Jesse I |
Director |
– • – |
2019-03-26 |
4 |
S |
$10.01 |
$968,397 |
I/I |
(96,743) |
8,763 |
|
- |
|
| Reed Joshua |
Chief Financial Officer |
• – – |
2019-03-05 |
4 |
A |
$0.00 |
$0 |
D/D |
29,637 |
29,637 |
|
- |
|
| Brady Todd C |
President and CEO |
• • – |
2019-03-05 |
4 |
A |
$0.00 |
$0 |
D/D |
250,000 |
556,054 |
|
- |
|
| Clark David J |
Chief Medical Officer |
• – – |
2019-03-05 |
4 |
A |
$0.00 |
$0 |
D/D |
3,503 |
11,512 |
|
- |
|
112 Records found
|
|
Page 3 of 5 |
|
|
0.01 (0.25%) 
